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a b s t r a c t
Imipramine is a tricyclic antidepressant inhibitor of norepinephrine and serotonin neuronal reuptake. The
roles of speciﬁc α1-adrenoceptor subtypes that might be targeted by the increased synaptic levels of
noradrenaline induced by imipramine are not well understood. This study investigates the α1-adrenoceptor
subtypes involved in the anti-immobility effect of imipramine in the mouse tail suspension test. The anti-
immobility effect of imipramine (32 mg/kg, i.p.) was signiﬁcantly antagonised by the non-subtype-selective
α1-adrenoceptor antagonist prazosin (0.5 and 1.0 mg/kg, i.p.). Neither the selective α1A-adrenoceptor
antagonist 5-methyl-3-[3-[3-[4-[2-(2,2,2,-triﬂuroethoxy)phenyl]-1-piperazinyl]propyl]-2,4-(1H,3H)-pyrimidi-
nedione (RS-100329, 0.5 and 1.0 mg/kg) nor the selective α1D-adrenoceptor antagonist 8-[2-[4-(2-methox-
yphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride, (BMY-7378, up to 1.0 mg/kg,
i.p.) affected the anti-immobility effect of imipramine. However, the anti-immobility effect of imipramine was
signiﬁcantly antagonised by the selective α1B-adrenoceptor antagonist (2S)-4-(4-amino-6,7-dimethoxy-2-
quinazolinyl)-2-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperazinecarboxylate (L-765,314). In addition, mice
treated only with RS-100329 or BMY-7378, but not with L-765,314, showed reduced immobility times in
comparison to mice treated with vehicle. These results indicate that the selective antagonism of α1A- and α1D-
adrenoceptors results in antidepressant-like effects and that the α1B-subtype is the main target for the
increased levels of noradrenaline caused by imipramine.
& 2015 Elsevier B.V. All rights reserved.
1. Introduction
Imipramine is the prototypic tricyclic antidepressant serendi-
pitously discovered by Roland Kuhn in 1956 while searching for a
compound with antipsychotic activity (Ban, 2001). The antide-
pressant activity of imipramine results from increases in synaptic
levels of serotonin and noradrenaline through inhibition of the
reuptake of these monoamines leading to increased activation of
the respective receptors. It is well stablished that α1-adrenoceptor
activation leads to positively motivated behaviours (Stone et al.,
2007) setting these receptors as targets for the increased levels of
noradrenaline caused by antidepressant drugs.
In the same concentration range in which imipramine and other
tricyclic antidepressants binds to and inhibit the noradrenaline
transporter, these drugs also interact with H1-histamine, 5-HT2-
serotonin, muscarinic cholinoceptors and α1-adrenoceptors, gener-
ally behaving as competitive antagonists. The antagonism of these
receptors results in clinically relevant effects including sedation (H1-
histamine receptors, Richelson, 1978), dry mouth and blurry vision
(muscarinic cholinoceptors, El-Fakahany and Richelson, 1983) and
postural hypotension (α1-adrenoceptors, U’Prichard et al., 1978).
As far as the noradrenergic neurotransmission is concerned, drugs
such as imipramine that in the same concentration range increase the
synaptic levels of noradrenaline and antagonise α1-adrenoceptors are
likely to produce self-cancelling effects because the α1-adrenoceptor
antagonism counteracts the sensitising inﬂuence of the inhibition of
noradrenaline reuptake (Nojimoto et al., 2010; Pupo et al., 1999).
There are three α1-adrenoceptor subtypes heterogeneously dis-
tributed in the central nervous system. Both α1A- and α1B-adreno-
ceptors are widely expressed in structures such as the amygdala,
hypothalamus, hippocampus, cortex, bridge and raphe nuclei (Papay
et al., 2006, 2004), whereas the α1D-subtype is found in lower den-
sities and concentrated in the hypothalamic paraventricular nucleus
and hippocampus (Sands and Morilak, 1999).
It was recently found that imipramine, amitriptyline and nort-
riptyline are much weaker antagonists of α1B-adrenoceptors than of
α1A- and α1D-subtypes; the afﬁnities of these tricyclic antidepres-
sants for α1B-adrenoceptors were approximately 10- to 80-fold lower
than the afﬁnities for the other two subtypes (Nojimoto et al., 2010).
These differential afﬁnities indicate that the α1-adrenoceptor subtype
which activation is most increased by the augmented noradrenaline
availability resultant from the blockade of neuronal reuptake is the
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α1B-adrenoceptor, whereas the α1A- and α1D-subtypes would be
affected by the self-cancelling effects of tricyclic antidepressants.
Interestingly, there is evidence that behavioral activity is increased by
activation of α1B-adrenoceptors (Stone et al., 2001).
The present study investigates the α1-adrenoceptor subtypes
involved in the anti-immobility effect of imipramine in the tail
suspension test in mice by determining the effects of the non-
selective α1-adrenoceptor antagonist prazosin and of the subtype
selective antagonists 5-Methyl-3-[3-[3-[4-[2-(2,2,2,-triﬂuroethoxy)
phenyl] -1- piperazinyl]propyl]-2,4-(1H,3H) -pyrimidinedione (RS-
100329, ﬃ100-fold selective for the α1A- vs α1B- and 50-fold vs
the α1D-subtypeWilliams et al., 1999), (2S)-4-(4-amino-6,7-dimeth-
oxy-2-quinazolinyl)-2-[[(1,1-dimethylethyl)amino]carbonyl]-1-pip-
erazinecarboxylate (L-765,314 ﬃ100-fold selective for the α1B- vs
α1A- and 10-fold vs the α1D-subtype Patane et al., 1998), and 8-[2-
[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-
7,9-dione dihydrochloride, (BMY-7378, ﬃ100-fold selective for the
α1D- vs α1A- and α1B-subtypes Goetz et al., 1995).
2. Material and methods
2.1. Animals
Swiss male mice (6 weeks of age old weighing 20 to 30 g) were
used. The mice were housed 10 per cage and had free access to food
and water until 1 h before the start of the experimental procedures.
The animal’s room was maintained at 2471 1C and 5575% humid-
ity with a 12-h light–dark cycle (lights on at 7:00 h). The experi-
mental procedures were performed between 10 h and 12:00 h and
were approved by the Ethics Committee for the Use of Experimental
Animals from UNESP—Botucatu (protocol number 418-CEUA).
2.2. Drugs and treatments
The following drugs were used: imipramine hydrochloride (Sigma
Chemical Co, USA), prazosin hydrochloride (Sigma RBI, Natick,
MA, USA), BMY-7378 dihydrochloride (Tocris Bioscience, Ellisville,
MO, USA), RS-100329 hydrochloride (Tocris Bioscience, Ellisville, MO,
USA) and L-765,314 hydrate (Sigma Chemical Co, USA). Mice were
separated into independent groups containing 7 to 9 animals. Each
drug was injected i.p. 30 min before the tail suspension test. In the
experiments designed to investigate the α1-adrenoceptor subtypes
involved in the anti-immobility effect of imipramine, the antagonists
prazosin, BMY-7378, RS-100329 and L-765,314 or the appropriate
vehicles (saline 0.9% for imipramine, prazosin, BMY-7378, RS-100329
and 2.5% DMSO for L-765,314) were injected i.p. 5 min before
imipramine. All drugs were administered in a volume of 10 ml/kg
body weight.
2.3. Tail suspension test
The tail suspension test is a widely used model for assessing
antidepressant-like activity in mice. In this test, mice submitted to
the inescapable stress of being suspended by their tail acquire an
immobile posture which duration is reduced by drugs with
antidepressant activity. The total duration of immobility induced
by tail suspension was measured according to the method
described by Steru et al. (1985). Brieﬂy, mice were suspended in
a frame 50 cm above the ﬂoor with the aid of an adhesive tape
placed approximately 1 cm from the tip of the tail. Immobility
time was recorded during 6 min.
2.4. Statistical analysis
Data is presented as mean7S.E.M. For multiple comparisons of
parametric data was used analysis of variance (ANOVA) followed
by post hoc Dunnett’s test. Statistical signiﬁcance was deﬁned as
Po0.05.
3. Results
Imipramine (32 mg/kg, i.p.) signiﬁcantly decreased the dura-
tion of immobility of mice in the tail suspension test (Fig. 1).
However, imipramine was unable to decrease the immobility of
mice pretreated with the non-subtype selective α1-adrenoceptor
antagonist prazosin (0.5 and 1.0 mg/kg, i.p.; Fig. 1). In addition,
mice treated only with 1.0 mg/kg prazosin (i.p.) presented incre-
ased immobility time in comparison to those treated with saline.
Neither imipramine (32 mg/kg, i.p.) nor prazosin (up to 1 mg/kg,
i.p.) or the combined treatment affected the locomotor activity of
mice as assessed by the number of falls in the rotarod test (data
not shown).
Differently from what was observed with prazosin, pretreat-
ment of mice with the selective α1A-adrenoceptor antagonist RS-
100329 (0.5 and 1.0 mg/kg, i.p.; Fig. 2) was unable to change the
anti-immobility effect of imipramine (32 mg/kg, i.p.) in the tail
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Fig. 1. Effects of the non-subtype selective α1-adrenoceptor antagonist prazosin
(0.5 and 1.0 mg/kg, i.p.) on the duration of immobility of mice treated with vehicle
(saline) or imipramine (32 mg/kg, i.p.) in the tail suspension test. Each column
represents the mean7S.E.M. for 9–15 mice. **Po0.01 and ***Po0.001 vs saline; n.
s., not signiﬁcant.
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Fig. 2. Effects of the selective α1A-adrenoceptor antagonist RS-100329 (RS, 0.1 to
1.0 mg/kg, i.p.) on the duration of immobility of mice treated with vehicle (saline)
or imipramine (32 mg/kg, i.p.) in the tail suspension test. Each column represents
the mean7S.E.M. for 8–24 mice. *Po0.05, **Po0.01 and ***Po0.001 vs saline; n.s.,
not signiﬁcant.
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suspension test. Moreover, mice treated only with RS-100329 (0.1
to 0.5 mg/kg, i.p.) presented reduced immobility times compared
to those treated with vehicle (Fig. 2).
The selective α1B-adrenoceptor antagonist L-765,314 (1.0 mg/kg,
i.p.; Fig. 3) signiﬁcantly reduced the anti-immobility effect of imip-
ramine (32 mg/kg, i.p.). In addition, the immobility time of mice
treated only with L-765,314 (0.5 and 1.0 mg/kg, i.p.) were not
different from that found in mice treated with saline or vehicle
(2.5% DMSO) (Fig. 3).
Pretreatment of mice with the selective α1D-adrenoceptor antago-
nist BMY-7378 (0.5 and 1.0 mg/kg, i.p.) was unable to change the anti-
immobility effect of imipramine (32 mg/kg, i.p.; Fig. 4), whereas mice
treated only with BMY-7378 (0.25 mg/kg, i.p.) presented reduced
immobility time in comparison to those treated with vehicle.
4. Discussion
Although it is well established that the antidepressant-like effe-
cts produced by imipramine and other tricyclic antidepressants is
related to the inhibition of noradrenaline reuptake and subsequent
increase in extracellular noradrenaline concentrations, the role of
speciﬁc α1-adrenoceptor subtypes which might be targeted by the
increased neurotransmitter synaptic levels are not well understood.
The present study shows that subtype selective and non-selective
α1-adrenoceptor antagonists affect differently the immobility times
of mice in the tail suspension test and interfere with the effect of
imipramine in this essay. Treatment of mice with imipramine sign-
iﬁcantly reduced the immobility times, whereas this anti-immo-
bility effect of imipramine was not observed in mice pretreated
with the non-selective subtype α1-adrenoceptor antagonist prazo-
sin indicating the participation of α1-adrenoceptors. In addition,
prazosin increased the immobility times of mice pretreated with
saline and this effect was not due to an impairment of locomotor
activity. Similar results with prazosin in the tail suspension test
have been previously described by other studies (Hascoet et al.,
1991; Hirano et al., 2007; Stone and Quartermain, 1999).
The subtype selective antagonists RS-100329 (α1A) and BMY-
7378 (α1D) were not able to change the anti-immobility effect of
imipramine indicating that activation of α1A- and α1D-adrenocep-
tor is not required. On the other hand, the anti-immobility effect of
imipramine was signiﬁcantly reduced by the selective α1B-adre-
noceptor antagonist L-765,314 pointing that α1B-adrenoceptors are
involved in the antidepressant-like effect of imipramine. Further-
more, the fact that mice treated with low doses of RS-100329 (0.1
to 0.5 mg/kg, i.p.) and BMY-7378 (0.25 mg/kg, i.p.) presented red-
uced immobility times in comparison to those treated with saline
point that the antagonism of α1A- and α1D-adrenoceptors results
in antidepressant-like effects. However, the duration of immobility
of mice treated with the highest doses of RS-100329 (1.0 mg/kg,
i.p.) or BMY-7378 (0.5 and 1.0 mg/kg, i.p.) was not different from
that observed in mice treated with saline and this lack of effect
may result from a loss of selectivity of these drugs. BMY-7378 is a
buspirone analogue that also shows high afﬁnity and low efﬁcacy
at 5-HT1A serotonin receptors (Dunlop et al., 1998). However, it
was shown that buspirone (3 to 30 mg/kg, i.p.) has no effect in the
duration of immobility of gerbil in the tail suspension test (Varty
et al., 2003), indicating that the effect observed with the lowest
dose of BMY-7378 in the present study is not related to its actions
at 5-HT1A serotonin receptors.
Several structures of the central nervous system are involved in
motivated behaviour, and the locus coeruleus and hypothalamus
appear to have an important as intraventricular α1-adrenoceptor
agonist infusion induces c-Fos activation and reduces immobility
time of mice in the tail suspension test (Stone et al., 2011).
In conjunction, the effects of the selective antagonists suggest
that α1-adrenoceptor subtypes have opposite roles in the tail susp-
ension test: α1A- and α1D-adrenoceptors antagonism do not inter-
fere with the effect of imipramine but reduces the duration of
immobility, whereas the antagonism of α1B-adrenoceptors signiﬁ-
cantly reduces the effects of imipramine but have no effect in the
duration of immobility. This suggestion is consistent with the
afﬁnity proﬁle of imipramine and other tricyclic antidepressants
for α1-adrenoceptor subtypes as these drugs behave as competitive
antagonists with much higher afﬁnity for α1A- and α1D-adrenocep-
tors than for α1B-adrenoceptors (Nojimoto et al., 2010). Hence, the
α1B-adrenoceptor is the subtype more likely to be targeted by the
increased synaptic levels of noradrenaline produced by imipramine,
since α1A- and α1D-adrenoceptors are predicted to be effectively
antagonised by this antidepressant. A recent study on the behaviour
of transgenic mice expressing constitutively active mutants of α1A-
and α1B-adrenoceptors reached different conclusions on the role of
these two receptor subtypes in the forced swim and tail suspension
test: the immobility time of mice expressing constitutively active
α1A-adrenoceptors was signiﬁcantly decreased, while immobility
time of mice expressing constitutively active α1B-adrenoceptors was
signiﬁcantly increased as compared with control wild type mice
(Doze et al., 2009). However, it is unknown whether compensatory
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Fig. 3. Effects of the selective α1B-adrenoceptor antagonist L-765,314 (L-765,
0.5 and 1.0 mg/kg, i.p.) on the duration of immobility of mice treated with vehicle
(saline and 2.5% DMSO) or imipramine (32 mg/kg, i.p.) in the tail suspension test.
Each column represents the mean7S.E.M. for 8–22 mice. *Po0.05 and ***Po0.001
vs saline or 2.5% DMSO; n.s., not signiﬁcant.
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Fig. 4. Effects of the selective α1D-adrenoceptor antagonist BMY-7378 (BMY, 0.25 to
1.0 mg/kg, i.p.) on the duration of immobility of mice treated with vehicle (saline)
or imipramine (32 mg/kg, i.p.) in the tail suspension test. Each column represents
the mean7S.E.M. for 8–24 mice. *Po0.05, **Po0.01 and ***Po0.001 vs saline; n.s.,
not signiﬁcant.
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mechanisms triggered by the chronically elevated α1A- and α1B-
adrenoceptor signalling take place in the manifestation of these two
phenotypes.
The lower afﬁnities of imipramine and other tricyclic antidepres-
sants for α1B-adrenoceptors may be important for the behavioural
effects of these drugs. In a comprehensive pharmacologic study emp-
loying ﬁve subtype selective antagonists including 5-methylurapidil,
BMY-7378, benoxathian, WB4101 and phentolamine, demonstrated a
deﬁnite role for α1B-adrenoceptors in motor activity and spontaneous
movement in mice subject to a novel environment; the potencies of
these antagonists in inhibiting forward movements and head move-
ments of mice placed in a fresh cage correlated well with the
afﬁnities of these drugs at α1B-adrenoceptors, but not at α1A-, α1D-
adrenoceptors or 5-HT1A receptors (Stone et al., 2001). In addition,
the stimulant effect of modaﬁnil in gross movement of mice was
inhibited only by high doses of WB4101 and BMY-7378 and was
signiﬁcantly reduced in mice knockout for α1B-adrenoceptors, further
supporting the involvement of α1B-adrenoceptors in behavioural
activation (Stone et al., 2002).
In conclusion, the effects of selective antagonists indicate that α1-
adrenoceptor subtypes have opposite roles in the behaviour of mice
in the tail suspension test and that activation of the α1B-adrenocep-
tors associated with antagonism of α1A- and α1D-adrenoceptors
might be one of the mechanisms involved in the antidepressant-
like activity of imipramine and other tricyclic antidepressants.
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